Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 185: 27-38, 2011 Jun 30.
Article in English | MEDLINE | ID: mdl-21504782

ABSTRACT

Late-phase long-term depression (L-LTD) in middle-aged mice has been difficult to achieve and maintain. Here we report an electrically induced, homosynaptic, input-specific form of LTD that could be stably maintained for at least 4 h in the CA1 area of hippocampal slices of 10-14 months old mice. This form of L-LTD was similar in magnitude in aged, middle-aged and young mice and was blocked by high concentrations of broad-spectrum N-methyl-d-aspartate receptor (NMDAR) antagonists such as d(-)-2-amino-5-phospho-pentanoic acid (d-AP5) and (R)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP). Extracellular and whole cell recordings revealed a decreased sensitivity to d-AP5 with age, without any differences in NMDAR conductance between the age groups tested. This L-LTD could be inhibited neither by common doses of NMDA-subunit specific antagonists like zinc, ifenprodil and Ro-25-6981, nor by various co-applications of these compounds. In addition to the lack of any GluN2 subunit bias, L-LTD did not show any discernible involvement of L-type voltage-gated calcium channels. In conclusion, our results do not support any specific role of NMDAR subunits in LTD.


Subject(s)
Hippocampus/cytology , Long-Term Synaptic Depression/physiology , Neurons/physiology , Receptors, AMPA/metabolism , Receptors, N-Methyl-D-Aspartate/physiology , Aging , Animals , Calcium Channel Blockers/pharmacology , Diazonium Compounds/pharmacology , Electric Stimulation/methods , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/classification , Excitatory Amino Acid Antagonists/pharmacology , Hippocampus/drug effects , Long-Term Synaptic Depression/drug effects , Mice , Mice, Inbred C57BL , N-Methylaspartate/pharmacology , Neurons/drug effects , Nifedipine/pharmacology , Patch-Clamp Techniques/methods , Pyridines/pharmacology
2.
Curr Med Chem ; 17(24): 2608-35, 2010.
Article in English | MEDLINE | ID: mdl-20491632

ABSTRACT

L-glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). Although just a few glutamate receptor ligands have turned out to be clinically useful, primarily because of unfavorable psychotropic side effects, the glutamate system remains an attractive molecular target in the treatment of epilepsy, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's chorea), schizophrenia, ischemia, pain, alcoholism and mood disorders. Knowledge about the structure of ionotropic glutamate receptors (iGluRs) at atomic resolution is vital for the determination of their physiological and pathological importance and, thus, for drug design. Recently, tremendous progress has been made in structure elucidation and understanding of the functioning of iGluRs. The data about general topology and modular composition of iGluRs as well as numerous crystal structures of ligand binding domains of many iGluR subtypes has been supplemented with the first molecular models of the whole receptor protein, followed by the first crystal structures of N-terminal domains and finally by the first crystal structure of the whole tetrameric iGluR. This review summarizes experimental and computational efforts to determine iGluR molecular architecture and focus on the above listed achievements of the last years. In particular, the aspects of iGluR structure which are important for drug design, like the molecular characterstics of the ligand binding sites, are depicted in detail.


Subject(s)
Models, Molecular , Receptors, Ionotropic Glutamate/chemistry , Animals , Binding Sites , Drug Design , Excitatory Amino Acid Antagonists/chemistry , Excitatory Amino Acid Antagonists/classification , Humans , Piperidines/chemistry , Protein Structure, Tertiary , Receptors, Ionotropic Glutamate/classification
3.
Eur J Pharmacol ; 639(1-3): 99-105, 2010 Aug 10.
Article in English | MEDLINE | ID: mdl-20371235

ABSTRACT

Schizophrenic patients typically exhibit impairment of sensorimotor gating, which can be modeled in animals using acoustic prepulse inhibition of the startle. Both classical and atypical antipsychotics have been shown to improve prepulse inhibition in DBA/2J mice, a non-pharmacological model for impaired sensorimotor gating. The purpose of the present study was to clarify whether metabotropic glutamate receptors participate in control of sensorimotor gating. We evaluated various metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice. This basal level of prepulse inhibition in DBA/2J mice was increased by only the mGlu(1) receptor antagonists [2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one] (CFMTI), 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-alpha]benzimidazole-2-carboxamide hydrochloride (YM-298198), and (3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone (JNJ16259685). There was no effect after treatments with the mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP), the mGlu(2/3) receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), the mGlu(2/3) receptor antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), the mGlu(7) receptor agonist N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the mGlu(7) receptor antagonist 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), or the mGlu(8) receptor agonist (S)-3,4-dicarboxyphenylglycine (DCPG). These findings indicate that inhibition of mGlu(1) receptor selectively increases prepulse inhibition in DBA/2J mice and suggest that mGlu(1) receptor antagonists could be a novel treatment for some aspects of schizophrenia.


Subject(s)
Excitatory Amino Acid Antagonists/pharmacology , Neural Inhibition/drug effects , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Animals , Antipsychotic Agents/classification , Antipsychotic Agents/pharmacology , Antipsychotic Agents/therapeutic use , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/classification , Excitatory Amino Acid Antagonists/therapeutic use , Ligands , Male , Mice , Mice, Inbred DBA , Neural Inhibition/physiology , Receptors, Metabotropic Glutamate/classification , Receptors, Metabotropic Glutamate/metabolism , Schizophrenia/drug therapy
5.
Synapse ; 56(4): 205-16, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15803497

ABSTRACT

Three metabotropic glutamate receptor subtype 5 (mGluR5) PET tracers have been labeled with either carbon-11 or fluorine-18 and their in vitro and in vivo behavior in rhesus monkey has been characterized. Each of these tracers share the common features of high affinity for mGluR5 (0.08-0.23 nM vs. rat mGluR5) and moderate lipophilicity (log P 2.8-3.4). Compound 1b was synthesized using a Suzuki or Stille coupling reaction with [11C]MeI. Compounds 2b and 3b were synthesized by a SNAr reaction using a 3-chlorobenzonitrile precursor. Autoradiographic studies in rhesus monkey brain slices using 2b and 3b showed specific binding in cortex, caudate, putamen, amygdala, hippocampus, most thalamic nuclei, and lower binding in the cerebellum. PET imaging studies in monkey showed that all three tracers readily enter the brain and provide an mGluR5-specific signal in all gray matter regions, including the cerebellum. The specific signal observed in the cerebellum was confirmed by the autoradiographic studies and saturation binding experiments that showed tracer binding in the cerebellum of rhesus monkeys. In vitro metabolism studies using the unlabeled compounds showed that 1a, 2a, and 3a are metabolized slower by human liver microsomes than by monkey liver microsomes. In vivo metabolism studies showed 3b to be long-lived in rhesus plasma with only one other more polar metabolite observed.


Subject(s)
Brain/metabolism , Excitatory Amino Acid Antagonists/chemical synthesis , Positron-Emission Tomography , Receptors, Metabotropic Glutamate/metabolism , Animals , Autoradiography/methods , Binding Sites/drug effects , Brain/anatomy & histology , Brain/diagnostic imaging , Brain/drug effects , Brain Chemistry , Brain Mapping , Carbon Radioisotopes/pharmacokinetics , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/classification , Excitatory Amino Acid Antagonists/pharmacokinetics , Fluorine Radioisotopes/pharmacokinetics , Humans , In Vitro Techniques , Macaca mulatta , Magnetic Resonance Imaging , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Rats , Receptor, Metabotropic Glutamate 5 , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Statistics as Topic , Time Factors
6.
Psychopharmacology (Berl) ; 167(3): 225-34, 2003 May.
Article in English | MEDLINE | ID: mdl-12669179

ABSTRACT

RATIONALE: Behavioral sensitization has been accorded a central role in contemporary theories of drug addiction. Accordingly, a substantial effort has been made to determine the processes mediating sensitization to psychostimulants. However, few studies have examined the mechanisms underlying sensitization to ethanol. OBJECTIVES: Experiments were conducted to assess the role of N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptors in expression of sensitization to ethanol's locomotor stimulant effects. METHODS: Sensitization was induced in DBA/2 J mice by administering ethanol (2 g/kg) intraperitoneally (i.p.) before four activity trials. Control groups were given saline (12.5 ml/kg i.p.) before each activity trial. Subsequently, the effects of two NMDA receptor antagonists, MK-801 and ifenprodil, and two non-NMDA glutamate receptor antagonists, DNQX and GYKI 52466, were assessed on expression of the sensitized locomotor response. RESULTS: MK-801 reduced the stimulant effects of ethanol and completely prevented expression of sensitization at doses exceeding 0.075 mg/kg. In contrast, although ifenprodil also reduced the stimulant effects of ethanol, the antagonist did not alter expression of sensitization. Non-NMDA glutamate antagonists were more consistent in their effects on sensitization. DNQX reduced the magnitude of the sensitized response at a low dose that did not alter the stimulant effects of ethanol. The more selective AMPA antagonist GYKI 52466 reduced the stimulant effects of ethanol and completely blocked expression of sensitization. CONCLUSIONS: The results provide initial evidence to suggest that both NMDA and non-NMDA glutamate receptors play a role in expression of sensitization to ethanol. Additional research will be required to elucidate the mechanisms underlying differences in the efficacy of glutamate antagonists.


Subject(s)
Central Nervous System Depressants/pharmacology , Ethanol/pharmacology , Motor Activity/drug effects , Receptors, Glutamate/physiology , Receptors, N-Methyl-D-Aspartate/physiology , Analysis of Variance , Animals , Behavior, Animal/drug effects , Central Nervous System Depressants/blood , Dose-Response Relationship, Drug , Drug Interactions , Drug Tolerance , Ethanol/blood , Excitatory Amino Acid Antagonists/classification , Excitatory Amino Acid Antagonists/pharmacology , Male , Mice , Mice, Inbred DBA , Receptors, N-Methyl-D-Aspartate/classification , Time Factors
7.
Behav Neurosci ; 112(4): 966-78, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9733203

ABSTRACT

A flavor paired with morphine shifted to the right the function relating morphine dose to tail-flick latencies and provoked hyperalgesic responses when rats were tested in the absence of morphine. These learned increases in nociceptive sensitivity were not mediated by alterations in tail-skin temperature. Microinjection of the competitive N-methyl-D-aspartate (NMDA) receptor antagonist D,L-2-amino-5-phosphonopentanoic acid (AP-5) into the lateral ventricle reversed the hyperalgesic responses but spared the tolerance to morphine analgesia. By contrast, systemic administration of the noncompetitive NMDA receptor antagonist MK-801 or intrathecal infusion of AP-5 reversed the hyperalgesic responses as well as the tolerance to morphine analgesia. The results demonstrate that associatively mediated tolerance to morphine analgesia can co-occur with hyperalgesic responses and are discussed relative to learned activation of endogenous pronociceptive mechanisms.


Subject(s)
Analgesics, Opioid/pharmacology , Association Learning/drug effects , Drug Tolerance/physiology , Excitatory Amino Acid Antagonists/pharmacology , Morphine/pharmacology , Pain Threshold/drug effects , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , 2-Amino-5-phosphonovalerate/pharmacology , Analysis of Variance , Animals , Association Learning/physiology , Binding, Competitive/physiology , Dizocilpine Maleate/pharmacology , Drinking Behavior/drug effects , Drug Administration Routes , Excitatory Amino Acid Antagonists/classification , Male , Pain Threshold/physiology , Rats , Rats, Wistar , Reaction Time/drug effects , Receptors, N-Methyl-D-Aspartate/physiology , Regression Analysis , Taste/physiology , Thermosensing/drug effects , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...